Inflammation and the Balance of Cytopathic versus Regulatory T Cells
炎症以及细胞病变与调节性 T 细胞的平衡
基本信息
- 批准号:7644028
- 负责人:
- 金额:$ 39.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferAllogenicAllograftingAnti-Inflammatory AgentsAnti-inflammatoryAntigensBreedingC57BL/6 MouseCD4 Positive T LymphocytesCellsClinicalCommitConditionCytoprotectionDataEngraftmentEnvironmentEquilibriumGraft RejectionGreen Fluorescent ProteinsImmune responseImmunityInbred BALB C MiceInbred NOD MiceInflammationInflammatoryInsulinInsulin ResistanceInterleukin-10Interleukin-17Interleukin-6Islet CellIslets of LangerhansIslets of Langerhans TransplantationKnock-in MouseMediatingMediator of activation proteinModelingMusOutcomePatternPhenotypeProtein C InhibitorRegulationResearch PersonnelRoleSignal TransductionSystemT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsTeaTestingTissuesTransgenic OrganismsTranslationsTransplantationTrypsinWorkconceptcytokinediabeticisletislet allograftpreventprogramspromoterresearch studyresilienceresponserestorationtool
项目摘要
We have long hypothesized that the balance of donor-reactive cytopathic effector T cells to donor reactive
graft protecting cells determines the outcome of the allograft response, namely rejection or tolerance. New
data and tools have emerged that prompt us"nowto examine the role of pro- and anti-inflammatory cytokines
upon the phenotype and function of antigen activated T cells in the allograft response, and upon graft
outcome itself. Our working model is that the commitment of alloreactive cells to a regulatory or graft-
destructive phenotype is governed by the balance of these cytokines. Our test systems will employ islet
allografts, a tissue known to be particularly vulnerable in the peri-operative period to toxic and noxious
insults. We further postulate that blockade of inflammation will provide cytoprotection that will promote
successful engraftment and assist in tolerance induction. In particular, we will focus on <xi-anti-trypsin(AAT),
an agent which our preliminary data shows to provide potent cytoprotection to islets. To perform this work
we have several lines of genetically manipulated mice, including bicistronic knock-in mice that express foxpS
and GFP under control of the foxpS promoter. These mice have been bred to the alloreactive TEa TCR
transgenic line. We also have founders for knock-in mice in which the 1L-17 promoterdrives expression of
lL-17 and RFP. These tools will be used as part of adoptive transfer systems along with detailed phenotypic,
expression, and functional analyses for the following: In aim #1, we will test the hypothesis that the Th17
subset of cells are uniquely potent in mediating rejection and opposing regulation; in aim #2, we will
determine whether AAT can alter the expression of pro- and anti-inflammatory cytokines within the graft and
reduce the islet mass needed to achieve euglycemia; and in aim #3, we will test whether the combination of
the cytoprotective and anti-inflammatory effects of AAT can synergize with costimulatory blockade to
suppress inflammation, promote regulation, and induce tolerance. As these agents are currently clinically
available, we feel that this work, if successful, has the potential for rapid translation into new clinical
approaches in islet transplantation.
长期以来,我们一直假设供者反应性致细胞病变效应T细胞与供者反应性致细胞病变效应T细胞之间的平衡,
移植物保护细胞决定同种异体移植反应的结果,即排斥或耐受。新
数据和工具的出现促使我们“现在去研究促炎和抗炎细胞因子的作用,
在同种异体移植物反应中抗原活化的T细胞的表型和功能,以及在移植物
结果本身。我们的工作模型是同种异体反应细胞对调节或移植物的承诺-
破坏性表型由这些细胞因子的平衡控制。我们的测试系统将采用胰岛
同种异体移植物,一种已知在围手术期特别容易受到有毒和有害物质影响的组织,
侮辱。我们进一步假设,阻断炎症将提供细胞保护,
成功植入并有助于耐受诱导。特别地,我们将关注<xi-抗胰蛋白酶(AAT),
我们的初步数据显示,该试剂可为胰岛提供有效的细胞保护。来完成这项工作
我们有几个基因操作的小鼠品系,包括表达foxpS的双顺反子基因敲入小鼠,
和在foxpS启动子控制下的GFP。这些小鼠已经被培育为同种异体反应性TEa TCR
转基因株系我们也有基因敲入小鼠的创始人,其中1 L-17启动子驱动
IL-17和RFP。这些工具将被用作过继转移系统的一部分,沿着详细的表型,
在目标#1中,我们将测试Th 17表达和功能分析的假设。
一个细胞亚群在介导排斥和对抗调节方面具有独特的效力;在目标#2中,我们将
确定AAT是否可以改变移植物内促炎和抗炎细胞因子的表达,
减少达到正常所需的胰岛质量;在目标#3中,我们将测试
AAT的细胞保护和抗炎作用可以与共刺激阻断协同作用,
抑制炎症、促进调节和诱导耐受。由于这些药物目前在临床上
我们认为,这项工作,如果成功,有可能迅速转化为新的临床
胰岛移植的方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY B. STROM其他文献
TERRY B. STROM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY B. STROM', 18)}}的其他基金
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7487996 - 财政年份:2007
- 资助金额:
$ 39.79万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7928084 - 财政年份:2007
- 资助金额:
$ 39.79万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7293367 - 财政年份:2007
- 资助金额:
$ 39.79万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
8117651 - 财政年份:2007
- 资助金额:
$ 39.79万 - 项目类别:
Inflammation and the Balance of Cytopathic versus Regulatory T Cells
炎症以及细胞病变与调节性 T 细胞的平衡
- 批准号:
7338986 - 财政年份:2007
- 资助金额:
$ 39.79万 - 项目类别:
Inflammation and T Cell Memory: Inter-related Barriers to Allograft Tolerance
炎症和 T 细胞记忆:同种异体移植耐受的相互关联的障碍
- 批准号:
7684588 - 财政年份:2007
- 资助金额:
$ 39.79万 - 项目类别:
Novel Approaches To Achieve Allograft Tolerance
实现同种异体移植耐受的新方法
- 批准号:
6532898 - 财政年份:2001
- 资助金额:
$ 39.79万 - 项目类别:
Novel Approaches To Achieve Allograft Tolerance
实现同种异体移植耐受的新方法
- 批准号:
6896086 - 财政年份:2001
- 资助金额:
$ 39.79万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 39.79万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 39.79万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 39.79万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 39.79万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




